{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:07:17Z","timestamp":1793725637028,"version":"4.6.1"},"reference-count":146,"publisher":"Bentham Science Publishers Ltd.","issue":"14","funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["2014\/13\/B\/NZ7\/02277"],"award-info":[{"award-number":["2014\/13\/B\/NZ7\/02277"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Huntington\u2019s disease (HD) is an inherited neurodegenerative disorder caused by a\nmutation in the gene that encodes a critical cell regulatory protein, huntingtin (Htt). The expansion\nof cytosine-adenine-guanine (CAG) trinucleotide repeats causes improper folding of\nfunctional proteins and is an initial trigger of pathological changes in the brain. Recent research\nhas indicated that the functional dysregulation of many transcription factors underlies\nthe neurodegenerative processes that accompany HD. These disturbances are caused not only\nby the loss of wild-type Htt (WT Htt) function but also by the occurrence of abnormalities\nthat result from the action of mutant Htt (mHtt).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In this review, we aim to describe the role of transcription factors that are currently thought to\nbe strongly associated with HD pathogenesis, namely, RE1-silencing transcription factor, also\nknown as neuron-restrictive silencer factor (REST\/NRSF), forkhead box proteins (FOXPs),\nperoxisome proliferator-activated receptor gamma coactivator-1a (PGC1\u03b1), heat shock transcription\nfactor 1 (HSF1), and nuclear factor \u03ba light-chain-enhancer of activated B cells (NF-\n\u03baB). We also take into account the role of these factors in the phenotype of HD as well as potential\npharmacological interventions targeting the analyzed proteins. Furthermore, we considered\nwhether molecular manipulation resulting in changes in transcription factor function\nmay have clinical potency for treating HD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200705225821","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T17:53:41Z","timestamp":1594058021000},"page":"2783-2806","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Transcriptional Dysregulation in Huntington\u2019s Disease: The Role in Pathogenesis and Potency for Pharmacological Targeting"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-9944","authenticated-orcid":true,"given":"Aleksandra","family":"Pogoda","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Medical University of Warsaw, Zwirki i Wigury Street 61, 02-097 Warsaw,Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9331-8285","authenticated-orcid":true,"given":"Natalia","family":"Chmielewska","sequence":"additional","affiliation":[{"name":"Department of Neurochemistry, Institute of Psychiatry and Neurology, Sobieskiego Street 9, 02-957 Warsaw,Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-361X","authenticated-orcid":true,"given":"Piotr","family":"Maciejak","sequence":"additional","affiliation":[{"name":"Department of Neurochemistry, Institute of Psychiatry and Neurology, Sobieskiego Street 9, 02-957 Warsaw,Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-5021","authenticated-orcid":true,"given":"Janusz","family":"Szyndler","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT, Medical University of Warsaw, Banacha Street 1B, 02-097 Warsaw,Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"MacDonald M.E.","year":"1993","unstructured":"MacDonald M.E.; Ambrose C.M.; Duyao M.P.; Myers R.H.; Lin C.; Srinidhi L.; Barnes G.; Taylor S.A.; James M.; Groot N.; MacFarlane H.; Jenkins B.; Anderson M.A.; Wexler N.S.; Gusella J.S.; The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 1993,72(6),971-983","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/1568013033483320","volume":"3","author":"Rubinsztein D.C.","year":"2003","unstructured":"Rubinsztein D.C.; The molecular pathology of Huntington\u2019s Disease (HD). Curr Med Chem Immunol Endocr Metab Agents 2003,3(4),329-334","journal-title":"Curr Med Chem Immunol Endocr Metab Agents"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"Roos R.A.","year":"2010","unstructured":"Roos R.A.; Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis 2010,5(40),40","journal-title":"Orphanet J Rare Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.3155875","volume":"227","author":"Graveland G.A.","year":"1985","unstructured":"Graveland G.A.; Williams R.S.; DiFiglia M.; Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington\u2019s disease. Science 1985,227(4688),770-773","journal-title":"Science"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"Vonsattel J.P.","year":"1998","unstructured":"Vonsattel J.P.; DiFiglia M.; Huntington disease. J Neuropathol Exp Neurol 1998,57(5),369-384","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jns.2010.11.015","volume":"301","author":"Panegyres P.K.","year":"2011","unstructured":"Panegyres P.K.; Goh J.G.S.; The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene. J Neurol Sci 2011,301(1-2),14-20","journal-title":"J Neurol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1566-2772(03)00059-8","volume":"3","author":"Luthi-Carter R.","year":"2003","unstructured":"Luthi-Carter R.; Cha J.H.; Mechanisms of transcriptional dysregulation in Huntington\u2019s disease. Clin Neurosci Res 2003,3,165-177","journal-title":"Clin Neurosci Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nn.4256","volume":"19","author":"Langfelder P.","year":"2016","unstructured":"Langfelder P.; Cantle J.P.; Chatzopoulou D.; Wang N.; Gao F.; Al-Ramahi I.; Lu X.H.; Ramos E.M.; El-Zein K.; Zhao Y.; Deverasetty S.; Tebbe A.; Schaab C.; Lavery D.J.; Howland D.; Kwak S.; Botas J.; Aaronson J.S.; Rosinski J.; Coppola G.; Horvath S.; Yang X.W.; Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci 2016,19(4),623-633","journal-title":"Nat Neurosci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/hmg\/ddx006","volume":"26","author":"Ament S.A.","year":"2017","unstructured":"Ament S.A.; Pearl J.R.; Grindeland A.; St Claire J.; Earls J.C.; Kovalenko M.; Gillis T.; Mysore J.; Gusella J.F.; Lee J.M.; Kwak S.; Howland D.; Lee M.Y.; Baxter D.; Scherler K.; Wang K.; Geman D.; Carroll J.B.; MacDonald M.E.; Carlson G.; Wheeler V.C.; Price N.D.; Hood L.E.; High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington\u2019s disease CAG knock-in mice across multiple genetic backgrounds. Hum Mol Genet 2017,26(5),913-922","journal-title":"Hum Mol Genet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.2174\/0929867326666190621101909","volume":"27","author":"Tellone E.","year":"2020","unstructured":"Tellone E.; Galtieri A.; Ficarra S.; Reviewing the biochemical implications of normal and mutated huntingtin in Huntington\u2019s disease. Curr Med Chem 2020,27(31),5137-5158","journal-title":"Curr Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0278-5846(03)00021-6","volume":"27","author":"Hickey M.A.","year":"2003","unstructured":"Hickey M.A.; Chesselet M.F.; Apoptosis in Huntington\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 2003,27(2),255-265","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"Saudou F.","year":"2016","unstructured":"Saudou F.; Humbert S.; The Biology of huntingtin. Neuron 2016,89(5),910-926","journal-title":"Neuron"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e01267","DOI":"10.7554\/eLife.01267","volume":"3","author":"McClelland S.","year":"2014","unstructured":"McClelland S.; Brennan G.P.; Dub&#xE9; C.; Rajpara S.; Iyer S.; Richichi C.; Bernard C.; Baram T.Z.; The transcription factor NRSF contributes to epileptogenesis by selective repression of a subset of target genes. eLife 2014,3,e01267","journal-title":"eLife"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"Zuccato C.","year":"2003","unstructured":"Zuccato C.; Tartari M.; Crotti A.; Goffredo D.; Valenza M.; Conti L.; Cataudella T.; Leavitt B.R.; Hayden M.R.; Timmusk T.; Rigamonti D.; Cattaneo E.; Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003,35(1),76-83","journal-title":"Nat Genet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.4003","volume":"22","author":"Dickey A.S.","year":"2016","unstructured":"Dickey A.S.; Pineda V.V.; Tsunemi T.; Liu P.P.; Miranda H.C.; Gilmore-Hall S.K.; Lomas N.; Sampat K.R.; Buttgereit A.; Torres M.J.M.; Flores A.L.; Arreola M.; Arbez N.; Akimov S.S.; Gaasterland T.; Lazarowski E.R.; Ross C.A.; Yeo G.W.; Sopher B.L.; Magnuson G.K.; Pinkerton A.B.; Masliah E.; La Spada A.R.; PPAR-&#x3B4; is repressed in Huntington\u2019s disease, is required for normal neuronal function and can be targeted therapeutically. Nat Med 2016,22(1),37-45","journal-title":"Nat Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1093\/hmg\/dds132","volume":"21","author":"Tang B.","year":"2012","unstructured":"Tang B.; Becanovic K.; Desplats P.A.; Spencer B.; Hill A.M.; Connolly C.; Masliah E.; Leavitt B.R.; Thomas E.A.; Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Hum Mol Genet 2012,21(14),3097-3111","journal-title":"Hum Mol Genet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1016\/j.cub.2007.01.008","volume":"17","author":"Carter M.E.","year":"2007","unstructured":"Carter M.E.; Brunet A.; FOXO transcription factors. Curr Biol 2007,17(4),R113-R114","journal-title":"Curr Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1016\/j.celrep.2017.11.018","volume":"21","author":"Hachigian L.J.","year":"2017","unstructured":"Hachigian L.J.; Carmona V.; Fenster R.J.; Kulicke R.; Heilbut A.; Sittler A.; Pereira de Almeida L.; Mesirov J.P.; Gao F.; Kolaczyk E.D.; Heiman M.; Control of Huntington\u2019s disease-associated phenotypes by the striatum-enriched transcription factor Foxp2. Cell Rep 2017,21(10),2688-2695","journal-title":"Cell Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1523\/JNEUROSCI.3612-16.2017","volume":"37","author":"Louis Sam Titus A.S.C.","year":"2017","unstructured":"Louis Sam Titus A.S.C.; Yusuff T.; Cassar M.; Thomas E.; Kretzschmar D.; D\u2019Mello S.R.; Reduced expression of Foxp1 as a contributing factor in Huntington\u2019s Disease. J Neurosci 2017,37(27),6575-6587","journal-title":"J Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","volume":"2","author":"Li J.Y.","year":"2005","unstructured":"Li J.Y.; Popovic N.; Brundin P.; The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies. NeuroRx 2005,2(3),447-464","journal-title":"NeuroRx"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2003.12.005","volume":"72","author":"Becker E.B.","year":"2004","unstructured":"Becker E.B.; Bonni A.; Cell cycle regulation of neuronal apoptosis in development and disease. Prog Neurobiol 2004,72(1),1-25","journal-title":"Prog Neurobiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bbadis.2006.12.003","volume":"1772","author":"Greene L.A.","year":"2007","unstructured":"Greene L.A.; Liu D.X.; Troy C.M.; Biswas S.C.; Cell cycle molecules define a pathway required for neuron death in development and disease. Biochim Biophys Acta 2007,1772(4),392-401","journal-title":"Biochim Biophys Acta"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/jnr.10638","volume":"73","author":"Takahashi K.","year":"2003","unstructured":"Takahashi K.; Liu F.C.; Hirokawa K.; Takahashi H.; Expression of Foxp2, a gene involved in speech and language, in the developing and adult striatum. J Neurosci Res 2003,73(1),61-72","journal-title":"J Neurosci Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1111\/febs.12418","volume":"280","author":"Lee C.Y.","year":"2013","unstructured":"Lee C.Y.; Cantle J.P.; Yang X.W.; Genetic manipulations of mutant huntingtin in mice: new insights into Huntington\u2019s disease pathogenesis. FEBS J 2013,280(18),4382-4394","journal-title":"FEBS J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1021\/bi0623025","volume":"46","author":"Merrill M.A.","year":"2007","unstructured":"Merrill M.A.; Malik Z.; Akyol Z.; Bartos J.A.; Leonard A.S.; Hudmon A.; Shea M.A.; Hell J.W.; Displacement of alpha-actinin from the NMDA receptor NR1 C0 domain By Ca2+\/calmodulin promotes CaMKII binding. Biochemistry 2007,46(29),8485-8497","journal-title":"Biochemistry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/jcp.21001","volume":"211","author":"Zhang L.","year":"2007","unstructured":"Zhang L.; Zhao Y.; The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 2007,211(3),590-597","journal-title":"J Cell Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3892\/mco.2013.107","volume":"1","author":"Takenaka M.","year":"2013","unstructured":"Takenaka M.; Seki N.; Toh U.; Hattori S.; Kawahara A.; Yamaguchi T.; Koura K.; Takahashi R.; Otsuka H.; Takahashi H.; Iwakuma N.; Nakagawa S.; Fujii T.; Sasada T.; Yamaguchi R.; Yano H.; Shirouzu K.; Kage M.; FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 2013,1(4),625-632","journal-title":"Mol Clin Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/83713","volume":"27","author":"Bennett C.L.","year":"2001","unstructured":"Bennett C.L.; Christie J.; Ramsdell F.; Brunkow M.E.; Ferguson P.J.; Whitesell L.; Kelly T.E.; Saulsbury F.T.; Chance P.F.; Ochs H.D.; The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001,27(1),20-21","journal-title":"Nat Genet"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1002\/jnr.21770","volume":"86","author":"Takahashi K.","year":"2008","unstructured":"Takahashi K.; Liu F.C.; Hirokawa K.; Takahashi H.; Expression of Foxp4 in the developing and adult rat forebrain. J Neurosci Res 2008,86(14),3106-3116","journal-title":"J Neurosci Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.neuroscience.2010.10.023","volume":"172","author":"Tam W.Y.","year":"2011","unstructured":"Tam W.Y.; Leung C.K.; Tong K.K.; Kwan K.M.; Foxp4 is essential in maintenance of Purkinje cell dendritic arborization in the mouse cerebellum. Neuroscience 2011,172(172),562-571","journal-title":"Neuroscience"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0166-2236(93)90117-5","volume":"16","author":"Beal M.F.","year":"1993","unstructured":"Beal M.F.; Hyman B.T.; Koroshetz W.; Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993,16(4),125-131","journal-title":"Trends Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","volume":"71","author":"Aziz N.A.","year":"2008","unstructured":"Aziz N.A.; van der Burg J.M.M.; Landwehrmeyer G.B.; Brundin P.; Stijnen T.; Roos R.A.; EHDI Study Group. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008,71(19),1506-1513","journal-title":"Neurology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/35007527","volume":"404","author":"Lowell B.B.","year":"2000","unstructured":"Lowell B.B.; Spiegelman B.M.; Towards a molecular understanding of adaptive thermogenesis. Nature 2000,404(6778),652-660","journal-title":"Nature"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1093\/hmg\/ddi319","volume":"14","author":"Seong I.S.","year":"2005","unstructured":"Seong I.S.; Ivanova E.; Lee J.M.; Choo Y.S.; Fossale E.; Anderson M.; Gusella J.F.; Laramie J.M.; Myers R.H.; Lesort M.; MacDonald M.E.H.D.H.D.; CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005,14(19),2871-2880","journal-title":"Hum Mol Genet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0092-8674(00)81410-5","volume":"92","author":"Puigserver P.","year":"1998","unstructured":"Puigserver P.; Wu Z.; Park C.W.; Graves R.; Wright M.; Spiegelman B.M.; A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998,92(6),829-839","journal-title":"Cell"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2006.09.024","volume":"127","author":"St-Pierre J.","year":"2006","unstructured":"St-Pierre J.; Drori S.; Uldry M.; Silvaggi J.M.; Rhee J.; J&#xE4;ger S.; Handschin C.; Zheng K.; Lin J.; Yang W.; Simon D.K.; Bachoo R.; Spiegelman B.M.; Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006,127(2),397-408","journal-title":"Cell"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1371\/journal.pbio.0030101","volume":"3","author":"Leone T.C.","year":"2005","unstructured":"Leone T.C.; Lehman J.J.; Finck B.N.; Schaeffer P.J.; Wende A.R.; Boudina S.; Courtois M.; Wozniak D.F.; Sambandam N.; Bernal-Mizrachi C.; Chen Z.; Holloszy J.O.; Medeiros D.M.; Schmidt R.E.; Saffitz J.E.; Abel E.D.; Semenkovich C.F.; Kelly D.P.; PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005,3(4),e101","journal-title":"PLoS Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","volume":"4","author":"Weydt P.","year":"2006","unstructured":"Weydt P.; Pineda V.V.; Torrence A.E.; Libby R.T.; Satterfield T.F.; Lazarowski E.R.; Gilbert M.L.; Morton G.J.; Bammler T.K.; Strand A.D.; Cui L.; Beyer R.P.; Easley C.N.; Smith A.C.; Krainc D.; Luquet S.; Sweet I.R.; Schwartz M.W.; La Spada A.R.; Thermoregulatory and metabolic defects in Huntington\u2019s disease transgenic mice implicate PGC-1alpha in Huntington\u2019s disease neurodegeneration. Cell Metab 2006,4(5),349-362","journal-title":"Cell Metab"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","volume":"127","author":"Cui L.","year":"2006","unstructured":"Cui L.; Jeong H.; Borovecki F.; Parkhurst C.N.; Tanese N.; Krainc D.; Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006,127(1),59-69","journal-title":"Cell"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2004.09.013","volume":"119","author":"Lin J.","year":"2004","unstructured":"Lin J.; Wu P.H.; Tarr P.T.; Lindenberg K.S.; St-Pierre J.; Zhang C.Y.; Mootha V.K.; J&#xE4;ger S.; Vianna C.R.; Reznick R.M.; Cui L.; Manieri M.; Donovan M.X.; Wu Z.; Cooper M.P.; Fan M.C.; Rohas L.M.; Zavacki A.M.; Cinti S.; Shulman G.I.; Lowell B.B.; Krainc D.; Spiegelman B.M.; Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004,119(1),121-135","journal-title":"Cell"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fphys.2015.00063","volume":"6","author":"Wiggs M.P.","year":"2015","unstructured":"Wiggs M.P.; Can endurance exercise preconditioning prevention disuse muscle atrophy? Front Physiol 2015,6(6),63","journal-title":"Front Physiol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.1038\/s41598-017-09148-7","volume":"7","author":"Jesse S.","year":"2017","unstructured":"Jesse S.; Bayer H.; Alupei M.C.; Z&#xFC;gel M.; Mulaw M.; Tuorto F.; Malmsheimer S.; Singh K.; Steinacker J.; Schumann U.; Ludolph A.C.; Scharffetter-Kochanek K.; Witting A.; Weydt P.; Iben S.; Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntington\u2019s disease. Sci Rep 2017,7(1),8513","journal-title":"Sci Rep"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"142ra97","DOI":"10.1126\/scitranslmed.3003799","volume":"4","author":"Tsunemi T.","year":"2012","unstructured":"Tsunemi T.; Ashe T.D.; Morrison B.E.; Soriano K.R.; Au J.; Roque R.A.; Lazarowski E.R.; Damian V.A.; Masliah E.; La Spada A.R.; PGC-1&#x3B1; rescues Huntington\u2019s disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 2012,4(142),142ra97","journal-title":"Sci Transl Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"19894","DOI":"10.1074\/jbc.M114.570739","volume":"289","author":"Neueder A.","year":"2014","unstructured":"Neueder A.; Achilli F.; Moussaoui S.; Bates G.P.; Novel isoforms of heat shock transcription factor 1, HSF1&#x3B3;&#x3B1; and HSF1&#x3B3;&#x3B2;, regulate chaperone protein gene transcription. J Biol Chem 2014,289(29),19894-19906","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nrd3453","volume":"10","author":"Neef D.W.","year":"2011","unstructured":"Neef D.W.; Jaeger A.M.; Thiele D.J.; Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov 2011,10(12),930-944","journal-title":"Nat Rev Drug Discov"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/15548627.2016.1248018","volume":"13","author":"Watanabe Y.","year":"2017","unstructured":"Watanabe Y.; Tsujimura A.; Taguchi K.; Tanaka M.; HSF1 stress response pathway regulates autophagy receptor SQSTM1\/p62-associated proteostasis. Autophagy 2017,13(1),133-148","journal-title":"Autophagy"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/JHD-2012-120020","volume":"1","author":"Riva L.","year":"2012","unstructured":"Riva L.; Koeva M.; Yildirim F.; Pirhaji L.; Dinesh D.; Mazor T.; Duennwald M.L.; Fraenkel E.; Poly-glutamine expanded huntingtin dramatically alters the genome wide binding of HSF1. J Huntingtons Dis 2012,1(1),33-45","journal-title":"J Huntingtons Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"14405","DOI":"10.1038\/ncomms14405","volume":"8","author":"Gomez-Pastor R.","year":"2017","unstructured":"Gomez-Pastor R.; Burchfiel E.T.; Neef D.W.; Jaeger A.M.; Cabiscol E.; McKinstry S.U.; Doss A.; Aballay A.; Lo D.C.; Akimov S.S.; Ross C.A.; Eroglu C.; Thiele D.J.; Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington\u2019s disease. Nat Commun 2017,8(8),14405","journal-title":"Nat Commun"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11068-004-0514-8","volume":"33","author":"DiProspero N.A.","year":"2004","unstructured":"DiProspero N.A.; Chen E.Y.; Charles V.; Plomann M.; Kordower J.H.; Tagle D.A.; Early changes in Huntington\u2019s disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 2004,33(5),517-533","journal-title":"J Neurocytol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1371\/journal.pgen.0030082","volume":"3","author":"Kaltenbach L.S.","year":"2007","unstructured":"Kaltenbach L.S.; Romero E.; Becklin R.R.; Chettier R.; Bell R.; Phansalkar A.; Strand A.; Torcassi C.; Savage J.; Hurlburt A.; Cha G.H.; Ukani L.; Chepanoske C.L.; Zhen Y.; Sahasrabudhe S.; Olson J.; Kurschner C.; Ellerby L.M.; Peltier J.M.; Botas J.; Hughes R.E.; Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007,3(5),e82","journal-title":"PLoS Genet"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"Gauthier L.R.","year":"2004","unstructured":"Gauthier L.R.; Charrin B.C.; Borrell-Pag&#xE8;s M.; Dompierre J.P.; Rangone H.; Cordeli&#xE8;res F.P.; De Mey J.; MacDonald M.E.; Lessmann V.; Humbert S.; Saudou F.; Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004,118(1),127-138","journal-title":"Cell"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.1073\/pnas.0610628104","volume":"104","author":"Caviston J.P.","year":"2007","unstructured":"Caviston J.P.; Ross J.L.; Antony S.M.; Tokito M.; Holzbaur E.L.; Huntingtin facilitates dynein\/dynactin-mediated vesicle transport. Proc Natl Acad Sci USA 2007,104(24),10045-10050","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/hmg\/ddr075","volume":"20","author":"Munsie L.","year":"2011","unstructured":"Munsie L.; Caron N.; Atwal R.S.; Marsden I.; Wild E.J.; Bamburg J.R.; Tabrizi S.J.; Truant R.; Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet 2011,20(10),1937-1951","journal-title":"Hum Mol Genet"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1042\/BJ20090907","volume":"425","author":"Fuchs M.","year":"2009","unstructured":"Fuchs M.; Poirier D.J.; Seguin S.J.; Lambert H.; Carra S.; Charette S.J.; Landry J.; Identification of the key structural motifs involved in HspB8\/HspB6-Bag3 interaction. Biochem J 2009,425(1),245-255","journal-title":"Biochem J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"14405","DOI":"10.1038\/ncomms14405","volume":"13","author":"Gomez-Pastor R.","year":"2017","unstructured":"Gomez-Pastor R.; Burchfiel E.T.; Neef D.W.; Jaeger A.M.; Cabiscol E.; McKinstry S.U.; Doss A.; Aballay A.; Lo D.C.; Akimov S.S.; Ross C.A.; Eroglu C.; Thiele D.J.; Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington\u2019s disease. Nat Commun 2017,13(8),14405","journal-title":"Nat Commun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fncel.2019.00103","volume":"13","author":"Intihar T.A.","year":"2019","unstructured":"Intihar T.A.; Martinez E.A.; Gomez-Pastor R.; Mitochondrial dysfunction in Huntington\u2019s disease; interplay between HSF1, p53 and PGC-1&#x3B1; transcription factors. Front Cell Neurosci 2019,13,103","journal-title":"Front Cell Neurosci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","volume":"33","author":"Zeron M.M.","year":"2002","unstructured":"Zeron M.M.; Hansson O.; Chen N.; Wellington C.L.; Leavitt B.R.; Brundin P.; Hayden M.R.; Raymond L.A.; Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington\u2019s disease. Neuron 2002,33(6),849-860","journal-title":"Neuron"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.nbd.2015.11.020","volume":"86","author":"Kolodziejczyk K.","year":"2016","unstructured":"Kolodziejczyk K.; Raymond L.A.; Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model. Neurobiol Dis 2016,86,62-74","journal-title":"Neurobiol Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1126\/science.7871435","volume":"267","author":"Schoenherr C.J.","year":"1995","unstructured":"Schoenherr C.J.; Anderson D.J.; The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995,267(5202),1360-1363","journal-title":"Science"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"10458","DOI":"10.1073\/pnas.0401827101","volume":"101","author":"Bruce A.W.","year":"2004","unstructured":"Bruce A.W.; Donaldson I.J.; Wood I.C.; Yerbury S.A.; Sadowski M.I.; Chapman M.; G&#xF6;ttgens B.; Buckley N.J.; Genome-wide analysis of repressor element 1 silencing transcription factor\/neuron-restrictive silencing factor (REST\/NRSF) target genes. Proc Natl Acad Sci USA 2004,101(28),10458-10463","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1128\/MCB.20.6.2147-2157.2000","volume":"20","author":"Roopra A.","year":"2000","unstructured":"Roopra A.; Sharling L.; Wood I.C.; Briggs T.; Bachfischer U.; Paquette A.J.; Buckley N.J.; Transcriptional repression by neuron-restrictive silencer factor is mediated via the Sin3-histone deacetylase complex. Mol Cell Biol 2000,20(6),2147-2157","journal-title":"Mol Cell Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","volume":"363","author":"Glozak M.A.","year":"2005","unstructured":"Glozak M.A.; Sengupta N.; Zhang X.; Seto E.; Acetylation and deacetylation of non-histone proteins. Gene 2005,363,15-23","journal-title":"Gene"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1073\/pnas.96.17.9873","volume":"96","author":"Andr&#xE9;s M.E.","year":"1999","unstructured":"Andr&#xE9;s M.E.; Burger C.; Peral-Rubio M.J.; Battaglioli E.; Anderson M.E.; Grimes J.; Dallman J.; Ballas N.; Mandel G.; CoREST: a functional corepressor required for regulation of neural-specific gene expression. Proc Natl Acad Sci USA 1999,96(17),9873-9878","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.molcel.2004.05.026","volume":"14","author":"Roopra A.","year":"2004","unstructured":"Roopra A.; Qazi R.; Schoenike B.; Daley T.J.; Morrison J.F.; Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol Cell 2004,14(6),727-738","journal-title":"Mol Cell"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1523\/JNEUROSCI.3920-03.2004","volume":"24","author":"Baquet Z.C.","year":"2004","unstructured":"Baquet Z.C.; Gorski J.A.; Jones K.R.; Jones K.R.; Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 2004,24(17),4250-4258","journal-title":"J Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/nn.3214","volume":"15","author":"Rodenas-Ruano A.","year":"2012","unstructured":"Rodenas-Ruano A.; Ch&#xE1;vez A.E.; Cossio M.J.; Castillo P.E.; Zukin R.S.; REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors. Nat Neurosci 2012,15(10),1382-1390","journal-title":"Nat Neurosci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.brainresbull.2020.03.007","volume":"158","author":"Chmielewska N.","year":"2020","unstructured":"Chmielewska N.; Wawer A.; Maciejak P.; Turzy\u0144ska D.; Sobolewska A.; Sk&#xF3;rzewska A.; Osuch B.; P\u0142a&#x17A;nik A.; Szyndler J.; The role of REST\/NRSF, TrkB and BDNF in neurobiological mechanisms of different susceptibility to seizure in a PTZ model of epilepsy. Brain Res Bull 2020,158,108-115","journal-title":"Brain Res Bull"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1073\/pnas.0611704104","volume":"104","author":"Formisano L.","year":"2007","unstructured":"Formisano L.; Noh K.M.; Miyawaki T.; Mashiko T.; Bennett M.V.; Zukin R.S.; Ischemic insults promote epigenetic reprogramming of mu opioid receptor expression in hippocampal neurons. Proc Natl Acad Sci USA 2007,104(10),4170-4175","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.12740\/PP\/94375","volume":"53","author":"Chmielewska N.","year":"2019","unstructured":"Chmielewska N.; Szyndler J.; Maciejak P.; P\u0142a&#x17A;nik A.; Epigenetic mechanisms of stress and depression. Psychiatr Pol 2019,53(6),1413-1428","journal-title":"Psychiatr Pol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.nbd.2010.02.003","volume":"39","author":"Buckley N.J.","year":"2010","unstructured":"Buckley N.J.; Johnson R.; Zuccato C.; Bithell A.; Cattaneo E.; The role of REST in transcriptional and epigenetic dysregulation in Huntington\u2019s disease. Neurobiol Dis 2010,39(1),28-39","journal-title":"Neurobiol Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.1523\/JNEUROSCI.4278-06.2007","volume":"27","author":"Zuccato C.","year":"2007","unstructured":"Zuccato C.; Belyaev N.; Conforti P.; Ooi L.; Tartari M.; Papadimou E.; MacDonald M.; Fossale E.; Zeitlin S.; Buckley N.; Cattaneo E.; Widespread disruption of repressor element-1 silencing transcription factor\/neuron-restrictive silencer factor occupancy at its target genes in Huntington\u2019s disease. J Neurosci 2007,27(26),6972-6983","journal-title":"J Neurosci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1471-4159.2010.07122.x","volume":"116","author":"Soldati C.","year":"2011","unstructured":"Soldati C.; Bithell A.; Conforti P.; Cattaneo E.; Buckley N.J.; Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington\u2019s disease. J Neurochem 2011,116(3),415-425","journal-title":"J Neurochem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/0006-8993(82)90385-7","volume":"231","author":"Wong P.T.","year":"1982","unstructured":"Wong P.T.; McGeer P.L.; Rossor M.; McGeer E.G.; Ornithine aminotransferase in Huntington\u2019s disease. Brain Res 1982,231(2),466-471","journal-title":"Brain Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nbd.2016.02.004","volume":"89","author":"Guiretti D.","year":"2016","unstructured":"Guiretti D.; Sempere A.; Lopez-Atalaya J.P.; Ferrer-Montiel A.; Barco A.; Valor L.M.; Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington\u2019s disease in the absence of bulk changes. Neurobiol Dis 2016,89,190-201","journal-title":"Neurobiol Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","volume":"24","author":"Ferrante R.J.","year":"2004","unstructured":"Ferrante R.J.; Ryu H.; Kubilus J.K.; D\u2019Mello S.; Sugars K.L.; Lee J.; Lu P.; Smith K.; Browne S.; Beal M.F.; Kristal B.S.; Stavrovskaya I.G.; Hewett S.; Rubinsztein D.C.; Langley B.; Ratan R.R.; Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington\u2019s disease. J Neurosci 2004,24(46),10335-10342","journal-title":"J Neurosci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"Gardian G.","year":"2005","unstructured":"Gardian G.; Browne S.E.; Choi D.K.; Klivenyi P.; Gregorio J.; Kubilus J.K.; Ryu H.; Langley B.; Ratan R.R.; Ferrante R.J.; Beal M.F.; Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease. J Biol Chem 2005,280(1),556-563","journal-title":"J Biol Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nature05823","volume":"447","author":"Tahiliani M.","year":"2007","unstructured":"Tahiliani M.; Mei P.; Fang R.; Leonor T.; Rutenberg M.; Shimizu F.; Li J.; Rao A.; Shi Y.; The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 2007,447(7144),601-605","journal-title":"Nature"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm2083","volume":"8","author":"Perkins N.D.","year":"2007","unstructured":"Perkins N.D.; Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007,8(1),49-62","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0166-2236(96)01035-1","volume":"20","author":"O\u2019Neill L.A.","year":"1997","unstructured":"O\u2019Neill L.A.; Kaltschmidt C.; NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997,20(6),252-258","journal-title":"Trends Neurosci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nn1110","volume":"6","author":"Meffert M.K.","year":"2003","unstructured":"Meffert M.K.; Chang J.M.; Wiltgen B.J.; Fanselow M.S.; Baltimore D.; NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci 2003,6(10),1072-1078","journal-title":"Nat Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"9403","DOI":"10.1523\/JNEUROSCI.23-28-09403.2003","volume":"23","author":"Fridmacher V.","year":"2003","unstructured":"Fridmacher V.; Kaltschmidt B.; Goudeau B.; Ndiaye D.; Rossi F.M.; Pfeiffer J.; Kaltschmidt C.; Isra&#xEB;l A.; M&#xE9;met S.; Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J Neurosci 2003,23(28),9403-9408","journal-title":"J Neurosci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"11821","DOI":"10.1074\/jbc.M009253200","volume":"276","author":"Wellmann H.","year":"2001","unstructured":"Wellmann H.; Kaltschmidt B.; Kaltschmidt C.; Retrograde transport of transcription factor NF-kappa B in living neurons. J Biol Chem 2001,276(15),11821-11829","journal-title":"J Biol Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.tins.2009.04.001","volume":"32","author":"Jordan B.A.","year":"2009","unstructured":"Jordan B.A.; Kreutz M.R.; Nucleocytoplasmic protein shuttling: the direct route in synapse-to-nucleus signaling. Trends Neurosci 2009,32(7),392-401","journal-title":"Trends Neurosci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"10356","DOI":"10.1523\/JNEUROSCI.18-24-10356.1998","volume":"18","author":"Maggirwar S.B.","year":"1998","unstructured":"Maggirwar S.B.; Sarmiere P.D.; Dewhurst S.; Freeman R.S.; Nerve growth factor-dependent activation of NF-kappaB contributes to survival of sympathetic neurons. J Neurosci 1998,18(24),10356-10365","journal-title":"J Neurosci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<151:AID-SYN8>3.0.CO;2-P","volume":"35","author":"Albensi B.C.","year":"2000","unstructured":"Albensi B.C.; Mattson M.P.; Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000,35(2),151-159","journal-title":"Synapse"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1371\/journal.pone.0000589","volume":"2","author":"Mikenberg I.","year":"2007","unstructured":"Mikenberg I.; Widera D.; Kaus A.; Kaltschmidt B.; Kaltschmidt C.; Transcription factor NF-kappaB is transported to the nucleus via cytoplasmic dynein\/dynactin motor complex in hippocampal neurons. PLoS One 2007,2(7),e589","journal-title":"PLoS One"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1093\/hmg\/ddq358","volume":"19","author":"Marcora E.","year":"2010","unstructured":"Marcora E.; Kennedy M.B.; The Huntington\u2019s disease mutation impairs Huntingtin\u2019s role in the transport of NF-&#x3BA;B from the synapse to the nucleus. Hum Mol Genet 2010,19(22),4373-4384","journal-title":"Hum Mol Genet"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/emboj.2008.133","volume":"27","author":"Colin E.","year":"2008","unstructured":"Colin E.; Zala D.; Liot G.; Rangone H.; Borrell-Pag&#xE8;s M.; Li X.J.; Saudou F.; Humbert S.; Huntingtin phosphorylation acts as a molecular switch for anterograde\/retrograde transport in neurons. EMBO J 2008,27(15),2124-2134","journal-title":"EMBO J"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","volume":"24","author":"Trushina E.","year":"2004","unstructured":"Trushina E.; Dyer R.B.; Badger J.D.; Ure D.; Eide L.; Tran D.D.; Vrieze B.T.; Legendre-Guillemin V.; McPherson P.S.; Mandavilli B.S.; Van Houten B.; Zeitlin S.; McNiven M.; Aebersold R.; Hayden M.; Parisi J.E.; Seeberg E.; Dragatsis I.; Doyle K.; Bender A.; Chacko C.; McMurray C.T.; Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 2004,24(18),8195-8209","journal-title":"Mol Cell Biol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/sj.cdd.4401837","volume":"13","author":"Mattson M.P.","year":"2006","unstructured":"Mattson M.P.; Meffert M.K.; Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006,13(5),852-860","journal-title":"Cell Death Differ"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"Tr&#xE4;ger U.","year":"2014","unstructured":"Tr&#xE4;ger U.; Andre R.; Lahiri N.; Magnusson-Lind A.; Andreas A.; Grueninger S.; McKinnon Ch.; Sirinathsinghji E.; Kahlon S.; Pfister E.L.; Moser R.; Hummerich H.; Antoniou M.; Bates G.P.; Luthi-Carter R.; Lowdell M.W.; Bj&#xF6;rkqvist M.; Ostroff G.R.; Aronin N.; Tabrizi S.J.; HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NFkB pathway dysregulation. Brain 2014,137(3),819-833","journal-title":"Brain"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"Politis M.","year":"2011","unstructured":"Politis M.; Pavese N.; Tai Y.F.; Kiferle L.; Mason S.L.; Brooks D.J.; Tabrizi S.J.; Barker R.A.; Piccini P.; Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study. Hum Brain Mapp 2011,32(2),258-270","journal-title":"Hum Brain Mapp"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","volume":"92","author":"Beaumont V.","year":"2016","unstructured":"Beaumont V.; Zhong S.; Lin H.; Xu W.; Bradaia A.; Steidl E.; Gleyzes M.; Wadel K.; Buisson B.; Padovan-Neto F.E.; Chakroborty S.; Ward K.M.; Harms J.F.; Beltran J.; Kwan M.; Ghavami A.; H&#xE4;ggkvist J.; T&#xF3;th M.; Halldin C.; Varrone A.; Schaab C.; Dybowski J.N.; Elschenbroich S.; Lehtim&#xE4;ki K.; Heikkinen T.; Park L.; Rosinski J.; Mrzljak L.; Lavery D.; West A.R.; Schmidt C.J.; Zaleska M.M.; Munoz-Sanjuan I.; Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s disease models. Neuron 2016,92(6),1220-1237","journal-title":"Neuron"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.2174\/138161209789649303","volume":"15","author":"Rigamonti D.","year":"2009","unstructured":"Rigamonti D.; Mutti C.; Zuccato C.; Cattaneo E.; Contini A.; Turning REST\/NRSF dysfunction in Huntington\u2019s disease into a pharmaceutical target. Curr Pharm Des 2009,15(34),3958-3967","journal-title":"Curr Pharm Des"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1158\/1535-7163.MCT-04-0228","volume":"4","author":"Fuller G.N.","year":"2005","unstructured":"Fuller G.N.; Su X.; Price R.E.; Cohen Z.R.; Lang F.F.; Sawaya R.; Majumder S.; Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)\/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol Cancer Ther 2005,4(3),343-349","journal-title":"Mol Cancer Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","volume":"63","author":"Saw P.E.","year":"2020","unstructured":"Saw P.E.; Song E.W.; siRNA therapeutics: a clinical reality. Sci China Life Sci 2020,63(4),485-500","journal-title":"Sci China Life Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/jgm.1062","volume":"9","author":"Park I.K.","year":"2007","unstructured":"Park I.K.; Lasiene J.; Chou S.H.; Horner P.J.; Pun S.H.; Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine). J Gene Med 2007,9(8),691-702","journal-title":"J Gene Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"358370","DOI":"10.1155\/2012\/358370","volume":"2012","author":"Vagner T.","year":"2012","unstructured":"Vagner T.; Young D.; Mouravlev A.; Nucleic acid-based therapy approaches for Huntington\u2019s disease. Neurol Res Int 2012,2012,358370","journal-title":"Neurol Res Int"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/jnc.12090","volume":"124","author":"Soldati C.","year":"2013","unstructured":"Soldati C.; Bithell A.; Johnston C.; Wong K.Y.; Stanton L.W.; Buckley N.J.; Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington\u2019s disease. J Neurochem 2013,124(3),418-430","journal-title":"J Neurochem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"9025","DOI":"10.1128\/MCB.23.24.9025-9031.2003","volume":"23","author":"Shimojo M.","year":"2003","unstructured":"Shimojo M.; Hersh L.B.; REST\/NRSF-interacting LIM domain protein, a putative nuclear translocation receptor. Mol Cell Biol 2003,23(24),9025-9031","journal-title":"Mol Cell Biol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"34880","DOI":"10.1074\/jbc.M804183200","volume":"283","author":"Shimojo M.","year":"2008","unstructured":"Shimojo M.; Huntingtin regulates RE1-silencing transcription factor\/neuron-restrictive silencer factor (REST\/NRSF) nuclear trafficking indirectly through a complex with REST\/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued. J Biol Chem 2008,283(50),34880-34886","journal-title":"J Biol Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"e87923","DOI":"10.1371\/journal.pone.0087923","volume":"9","author":"Todd D.","year":"2014","unstructured":"Todd D.; Gowers I.; Dowler S.J.; Wall M.D.; McAllister G.; Fischer D.F.; Dijkstra S.; Fratantoni S.A.; van de Bospoort R.; Veenman-Koepke J.; Flynn G.; Arjomand J.; Dominguez C.; Munoz-Sanjuan I.; Wityak J.; Bard J.A.; A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington\u2019s disease. PLoS One 2014,9(2),e87923","journal-title":"PLoS One"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","volume":"33","author":"Simmons D.A.","year":"2013","unstructured":"Simmons D.A.; Belichenko N.P.; Yang T.; Condon C.; Monbureau M.; Shamloo M.; Jing D.; Massa S.M.; Longo F.M.; A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington\u2019s disease. J Neurosci 2013,33(48),18712-18727","journal-title":"J Neurosci"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1093\/hmg\/ddt098","volume":"22","author":"Jiang M.","year":"2013","unstructured":"Jiang M.; Peng Q.; Liu X.; Jin J.; Hou Z.; Zhang J.; Mori S.; Ross C.A.; Ye K.; Duan W.; Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington\u2019s disease. Hum Mol Genet 2013,22(12),2462-2470","journal-title":"Hum Mol Genet"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jnc.12348","volume":"127","author":"Conforti P.","year":"2013","unstructured":"Conforti P.; Zuccato C.; Gaudenzi G.; Ieraci A.; Camnasio S.; Buckley N.J.; Mutti C.; Cotelli F.; Contini A.; Cattaneo E.; Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington\u2019s disease models. J Neurochem 2013,127(1),22-35","journal-title":"J Neurochem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/stem.1430","volume":"31","author":"Charbord J.","year":"2013","unstructured":"Charbord J.; Poydenot P.; Bonnefond C.; Feyeux M.; Casagrande F.; Brinon B.; Francelle L.; Aur&#xE9;gan G.; Guillermier M.; Cailleret M.; Viegas P.; Nicoleau C.; Martinat C.; Brouillet E.; Cattaneo E.; Peschanski M.; Lechuga M.; Perrier A.L.; High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. Stem Cells 2013,31(9),1816-1828","journal-title":"Stem Cells"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"e1001717","DOI":"10.1371\/journal.pbio.1001717","volume":"11","author":"Mielcarek M.","year":"2013","unstructured":"Mielcarek M.; Landles C.; Weiss A.; Bradaia A.; Seredenina T.; Inuabasi L.; Osborne G.F.; Wadel K.; Touller C.; Butler R.; Robertson J.; Franklin S.A.; Smith D.L.; Park L.; Marks P.A.; Wanker E.E.; Olson E.N.; Luthi-Carter R.; van der Putten H.; Beaumont V.; Bates G.P.; HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 2013,11(11),e1001717","journal-title":"PLoS Biol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1073\/pnas.0804249105","volume":"105","author":"Thomas E.A.","year":"2008","unstructured":"Thomas E.A.; Coppola G.; Desplats P.A.; Tang B.; Soragni E.; Burnett R.; Gao F.; Fitzgerald K.M.; Borok J.F.; Herman D.; Geschwind D.H.; Gottesfeld J.M.; The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice. Proc Natl Acad Sci USA 2008,105(40),15564-15569","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","volume":"46","author":"Jia H.","year":"2012","unstructured":"Jia H.; Pallos J.; Jacques V.; Lau A.; Tang B.; Cooper A.; Syed A.; Purcell J.; Chen Y.; Sharma S.; Sangrey G.R.; Darnell S.B.; Plasterer H.; Sadri-Vakili G.; Gottesfeld J.M.; Thompson L.M.; Rusche J.R.; Marsh J.L.; Thomas E.A.; Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington\u2019s disease. Neurobiol Dis 2012,46(2),351-361","journal-title":"Neurobiol Dis"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1073\/pnas.1415195112","volume":"12","author":"Jia H.","year":"2015","unstructured":"Jia H.; Morris C.D.; Williams R.M.; Loring J.F.; Thomas E.A.; HDAC inhibition imparts beneficial transgenerational effects in Huntington\u2019s disease mice via altered DNA and histone methylation. Proc Natl Acad Sci USA 2015,12(1),56-64","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nature01667","volume":"423","author":"Puigserver P.","year":"2003","unstructured":"Puigserver P.; Rhee J.; Donovan J.; Walkey C.J.; Yoon J.C.; Oriente F.; Kitamura Y.; Altomonte J.; Dong H.; Accili D.; Spiegelman B.M.; Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003,423(6939),550-555","journal-title":"Nature"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/hmg\/ddq322","volume":"19","author":"Chiang M.C.","year":"2010","unstructured":"Chiang M.C.; Chen C.M.; Lee M.R.; Chen H.W.; Chen H.M.; Wu Y.S.; Hung C.H.; Kang J.J.; Chang C.P.; Chang C.; Wu Y.R.; Tsai Y.S.; Chern Y.; Modulation of energy deficiency in Huntington\u2019s disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 2010,19(20),4043-4058","journal-title":"Hum Mol Genet"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"25628","DOI":"10.1074\/jbc.M804291200","volume":"283","author":"Quintanilla R.A.","year":"2008","unstructured":"Quintanilla R.A.; Jin Y.N.; Fuenzalida K.; Bronfman M.; Johnson G.V.; Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem 2008,283(37),25628-25637","journal-title":"J Biol Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","volume":"21","author":"Johri A.","year":"2012","unstructured":"Johri A.; Calingasan N.Y.; Hennessey T.M.; Sharma A.; Yang L.; Wille E.; Chandra A.; Beal M.F.; Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 2012,21(5),1124-1137","journal-title":"Hum Mol Genet"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/hmg\/ddr482","volume":"21","author":"Yatsuga S.","year":"2012","unstructured":"Yatsuga S.; Suomalainen A.; Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet 2012,21(3),526-535","journal-title":"Hum Mol Genet"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1007\/s12035-016-0048-3","volume":"54","author":"Naia L.","year":"2017","unstructured":"Naia L.; Rosenstock T.R.; Oliveira A.M.; Oliveira-Sousa S.I.; Caldeira G.L.; Carmo C.; La&#xE7;o M.N.; Hayden M.R.; Oliveira C.R.; Rego A.C.; Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington\u2019s disease models. Mol Neurobiol 2017,54(7),5385-5399","journal-title":"Mol Neurobiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","volume":"88","author":"McGarry A.","year":"2017","unstructured":"McGarry A.; McDermott M.; Kieburtz K.; de Blieck E.A.; Beal F.; Marder K.; Ross C.; Shoulson I.; Gilbert P.; Mallonee W.M.; Guttman M.; Wojcieszek J.; Kumar R.; LeDoux M.S.; Jenkins M.; Rosas H.D.; Nance M.; Biglan K.; Como P.; Dubinsky R.M.; Shannon K.M.; O\u2019Suilleabhain P.; Chou K.; Walker F.; Martin W.; Wheelock V.L.; McCusker E.; Jankovic J.; Singer C.; Sanchez-Ramos J.; Scott B.; Suchowersky O.; Factor S.A.; Higgins D.S.; Molho E.; Revilla F.; Caviness J.N.; Friedman J.H.; Perlmutter J.S.; Feigin A.; Anderson K.; Rodriguez R.; McFarland N.R.; Margolis R.L.; Farbman E.S.; Raymond L.A.; Suski V.; Kostyk S.; Colcher A.; Seeberger L.; Epping E.; Esmail S.; Diaz N.; Fung W.L.; Diamond A.; Frank S.; Hanna P.; Hermanowicz N.; Dure L.S.; Cudkowicz M.; Huntington Study Group 2CARE Investigators and Coordinators. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 2017,88(2),152-159","journal-title":"Neurology"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1124\/jpet.106.114769","volume":"320","author":"Jiang J.","year":"2007","unstructured":"Jiang J.; Kurnikov I.; Belikova N.A.; Xiao J.; Zhao Q.; Amoscato A.A.; Braslau R.; Studer A.; Fink M.P.; Greenberger J.S.; Wipf P.; Kagan V.E.; Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther 2007,320(3),1050-1060","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.celrep.2012.10.001","volume":"2","author":"Xun Z.","year":"2012","unstructured":"Xun Z.; Rivera-S&#xE1;nchez S.; Ayala-Pe&#xF1;a S.; Lim J.; Budworth H.; Skoda E.M.; Robbins P.D.; Niedernhofer L.J.; Wipf P.; McMurray C.T.; Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington\u2019s disease. Cell Rep 2012,2(5),1137-1142","journal-title":"Cell Rep"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"e0194580","DOI":"10.1371\/journal.pone.0194580","volume":"13","author":"Polyzos A.A.","year":"2018","unstructured":"Polyzos A.A.; Wood N.I.; Williams P.; Wipf P.; Morton A.J.; McMurray C.T.; XJB-5-131-mediated improvement in physiology and behaviour of the R6\/2 mouse model of Huntington\u2019s disease is age- and sex- dependent. PLoS One 2018,13(4),e0194580","journal-title":"PLoS One"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1007\/s12035-016-0120-z","volume":"54","author":"Reis S.D.","year":"2017","unstructured":"Reis S.D.; Pinho B.R.; Oliveira J.M.A.; Modulation of molecular chaperones in Huntington\u2019s disease and other polyglutamine disorders. Mol Neurobiol 2017,54(8),5829-5854","journal-title":"Mol Neurobiol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1074\/jbc.M111.294801","volume":"287","author":"Baldo B.","year":"2012","unstructured":"Baldo B.; Weiss A.; Parker C.N.; Bibel M.; Paganetti P.; Kaupmann K.; A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. J Biol Chem 2012,287(2),1406-1414","journal-title":"J Biol Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1172\/JCI57413","volume":"121","author":"Labbadia J.","year":"2011","unstructured":"Labbadia J.; Cunliffe H.; Weiss A.; Katsyuba E.; Sathasivam K.; Seredenina T.; Woodman B.; Moussaoui S.; Frentzel S.; Luthi-Carter R.; Paganetti P.; Bates G.P.; Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 2011,121(8),3306-3319","journal-title":"J Clin Invest"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"e0220393","DOI":"10.1371\/journal.pone.0220393","volume":"14","author":"Orozco-D&#xED;az R.","year":"2019","unstructured":"Orozco-D&#xED;az R.; S&#xE1;nchez-&#xC1;lvarez A.; Hern&#xE1;ndez-Hern&#xE1;ndez J.M.; Tapia-Ram&#xED;rez J.; The interaction between RE1-silencing transcription factor (REST) and heat shock protein 90 as new therapeutic target against Huntington\u2019s disease. PLoS One 2019,14(7),e0220393","journal-title":"PLoS One"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jnc.13553","volume":"137","author":"Dobson L.","year":"2016","unstructured":"Dobson L.; Tr&#xE4;ger U.; Farmer R.; Hayardeny L.; Loupe P.; Hayden M.R.; Tabrizi S.J.; Laquinimod dampens hyperactive cytokine production in Huntington\u2019s disease patient myeloid cells. J Neurochem 2016,137(5),782-794","journal-title":"J Neurochem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.brainresbull.2014.02.007","volume":"102","author":"Gupta S.","year":"2014","unstructured":"Gupta S.; Sharma B.; Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-&#x3BA;B) modulation in experimental Huntington\u2019s disease. Brain Res Bull 2014,102,57-68","journal-title":"Brain Res Bull"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1471-4159.1993.tb05859.x","volume":"60","author":"Brouillet E.","year":"1993","unstructured":"Brouillet E.; Jenkins B.G.; Hyman B.T.; Ferrante R.J.; Kowall N.W.; Srivastava R.; Roy D.S.; Rosen B.R.; Beal M.F.; Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993,60(1),356-359","journal-title":"J Neurochem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","volume":"32","author":"Bouchard J.","year":"2012","unstructured":"Bouchard J.; Truong J.; Bouchard K.; Dunkelberger D.; Desrayaud S.; Moussaoui S.; Tabrizi S.J.; Stella N.; Muchowski P.J.; Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease. J Neurosci 2012,32(50),18259-18268","journal-title":"J Neurosci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","volume":"22","author":"Hsiao H.Y.","year":"2013","unstructured":"Hsiao H.Y.; Chen Y.C.; Chen H.M.; Tu P.H.; Chern Y.; A critical role of astrocyte-mediated nuclear factor-&#x3BA;B-dependent inflammation in Huntington\u2019s disease. Hum Mol Genet 2013,22(9),1826-1842","journal-title":"Hum Mol Genet"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellsig.2016.12.005","volume":"31","author":"Bowles K.R.","year":"2017","unstructured":"Bowles K.R.; Stone T.; Holmans P.; Allen N.D.; Dunnett S.B.; Jones L.; SMAD transcription factors are altered in cell models of HD and regulate HTT expression. Cell Signal 2017,31,1-14","journal-title":"Cell Signal"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"e7435","DOI":"10.15252\/msb.20167435","volume":"14","author":"Ament S.A.","year":"2018","unstructured":"Ament S.A.; Pearl J.R.; Cantle J.P.; Bragg R.M.; Skene P.J.; Coffey S.R.; Bergey D.E.; Wheeler V.C.; MacDonald M.E.; Baliga N.S.; Rosinski J.; Hood L.E.; Carroll J.B.; Price N.D.; Transcriptional regulatory networks underlying gene expression changes in Huntington\u2019s disease. Mol Syst Biol 2018,14(3),e7435","journal-title":"Mol Syst Biol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.nbd.2011.07.001","volume":"45","author":"Seredenina T.","year":"2012","unstructured":"Seredenina T.; Luthi-Carter R.; What have we learned from gene expression profiles in Huntington\u2019s disease? Neurobiol Dis 2012,45(1),83-98","journal-title":"Neurobiol Dis"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s12035-016-0010-4","volume":"54","author":"Niewiadomska-Cimicka A.","year":"2017","unstructured":"Niewiadomska-Cimicka A.; Krzy&#x17C;osiak A.; Ye T.; Podle&#x15B;ny-Drabiniok A.; Demb&#xE9;l&#xE9; D.; Doll&#xE9; P.; Kr\u0119&#x17C;el W.; Genome-wide analysis of RARb transcriptional targets in mouse striatum links retinoic acid signaling with Huntington\u2019s disease and other neurodegenerative disorders. Mol Neurobiol 2017,54(5),3859-3878","journal-title":"Mol Neurobiol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12920-014-0060-2","volume":"7","author":"Neueder A.","year":"2014","unstructured":"Neueder A.; Bates G.P.; A common gene expression signature in Huntington\u2019s disease patient brain regions. BMC Med Genomics 2014,7,60","journal-title":"BMC Med Genomics"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"e108961","DOI":"10.1371\/journal.pone.0108961","volume":"9","author":"Mielcarek M.","year":"2014","unstructured":"Mielcarek M.; Bondulich M.K.; Inuabasi L.; Franklin S.A.; Muller T.; Bates G.P.; The Huntington\u2019s disease-related cardiomyopathy prevents a hypertrophic response in the R6\/2 mouse model. PLoS One 2014,9(9),e108961","journal-title":"PLoS One"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"e14311","DOI":"10.1371\/journal.pone.0014311","volume":"5","author":"Ravache M.","year":"2010","unstructured":"Ravache M.; Weber C.; M&#xE9;rienne K.; Trottier Y.; Transcriptional activation of REST by Sp1 in Huntington\u2019s disease models. PLoS One 2010,5(12),e14311","journal-title":"PLoS One"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JHD-160211","volume":"5","author":"Vodicka P.","year":"2016","unstructured":"Vodicka P.; Chase K.; Iuliano M.; Tousley A.; Valentine D.T.; Sapp E.; Kegel-Gleason K.B.; Sena-Esteves M.; Aronin N.; DiFiglia M.; Autophagy activation by transcription factor EB (TFEB) in striatum of HDQ175\/Q7Mice. J Huntingtons Dis 2016,5(3),249-260","journal-title":"J Huntingtons Dis"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.mcn.2017.07.004","volume":"83","author":"Moily N.S.","year":"2017","unstructured":"Moily N.S.; Ormsby A.R.; Stojilovic A.; Ramdzan Y.M.; Diesch J.; Hannan R.D.; Zajac M.S.; Hannan A.J.; Oshlack A.; Hatters D.M.; Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington\u2019s disease pathways. Mol Cell Neurosci 2017,83,103-112","journal-title":"Mol Cell Neurosci"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1038\/emboj.2010.225","volume":"29","author":"Hayashida N.","year":"2010","unstructured":"Hayashida N.; Fujimoto M.; Tan K.; Prakasam R.; Shinkawa T.; Li L.; Ichikawa H.; Takii R.; Nakai A.; Heat shock factor 1 ameliorates proteotoxicity in cooperation with the transcription factor NFAT. EMBO J 2010,29(20),3459-3469","journal-title":"EMBO J"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/hmg\/dds040","volume":"21","author":"Vidal R.L.","year":"2012","unstructured":"Vidal R.L.; Figueroa A.; Court F.A.; Thielen P.; Molina C.; Wirth C.; Caballero B.; Kiffin R.; Segura-Aguilar J.; Cuervo A.M.; Glimcher L.H.; Hetz C.; Targeting the UPR transcription factor XBP1 protects against Huntington\u2019s disease through the regulation of FoxO1 and autophagy. Hum Mol Genet 2012,21(10),2245-2262","journal-title":"Hum Mol Genet"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1471-4159.2012.07711.x","volume":"121","author":"Anglada-Huguet M.","year":"2012","unstructured":"Anglada-Huguet M.; Giralt A.; Perez-Navarro E.; Alberch J.; Xifr&#xF3; X.; Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington\u2019s disease. J Neurochem 2012,121(4),639-648","journal-title":"J Neurochem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/1873-3468.12989","volume":"592","author":"Kang I.","year":"2018","unstructured":"Kang I.; Chu C.T.; Kaufman B.A.; The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms. FEBS Lett 2018,592(5),793-811","journal-title":"FEBS Lett"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1111\/febs.14379","volume":"285","author":"Dinkova-Kostova A.T.","year":"2018","unstructured":"Dinkova-Kostova A.T.; Kostov R.V.; Kazantsev A.G.; The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J 2018,285(19),3576-3590","journal-title":"FEBS J"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"E4676","DOI":"10.1073\/pnas.1614943114","volume":"114","author":"Quinti L.","year":"2017","unstructured":"Quinti L.; Dayalan Naidu S.; Tr&#xE4;ger U.; Chen X.; Kegel-Gleason K.; Ll&#xE8;res D.; Connolly C.; Chopra V.; Low C.; Moniot S.; Sapp E.; Tousley A.R.; Vodicka P.; Van Kanegan M.J.; Kaltenbach L.S.; Crawford L.A.; Fuszard M.; Higgins M.; Miller J.R.C.; Farmer R.E.; Potluri V.; Samajdar S.; Meisel L.; Zhang N.; Snyder A.; Stein R.; Hersch S.M.; Ellerby L.M.; Weerapana E.; Schwarzschild M.A.; Steegborn C.; Leavitt B.R.; Degterev A.; Tabrizi S.J.; Lo D.C.; DiFiglia M.; Thompson L.M.; Dinkova-Kostova A.T.; Kazantsev A.G.; KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington\u2019s disease patients. Proc Natl Acad Sci USA 2017,114(23),E4676-E4685","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00401-017-1770-2","volume":"134","author":"Hern&#xE1;ndez I.H.","year":"2017","unstructured":"Hern&#xE1;ndez I.H.; Torres-Peraza J.; Santos-Galindo M.; Ramos-Mor&#xF3;n E.; Fern&#xE1;ndez-Fern&#xE1;ndez M.R.; P&#xE9;rez-&#xC1;lvarez M.J.; Miranda-Vizuete A.; Lucas J.J.; The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington\u2019s disease. Acta Neuropathol 2017,134(6),839-850","journal-title":"Acta Neuropathol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1172\/JCI82670","volume":"126","author":"Naranjo J.R.","year":"2016","unstructured":"Naranjo J.R.; Zhang H.; Villar D.; Gonz&#xE1;lez P.; Dopazo X.M.; Mor&#xF3;n-Oset J.; Higueras E.; Oliveros J.C.; Arrabal M.D.; Prieto A.; Cerc&#xF3;s P.; Gonz&#xE1;lez T.; De la Cruz A.; Casado-Vela J.; R&#xE1;bano A.; Valenzuela C.; Gutierrez-Rodriguez M.; Li J-Y.; Mellstr&#xF6;m B.; Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease. J Clin Invest 2016,126(2),627-638","journal-title":"J Clin Invest"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200705225821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183490\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200705225821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T10:31:37Z","timestamp":1654425097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183490\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":146,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200705225821","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}